Affirming the importance of the Orphan Drug Act, applauding its lifesaving contributions over its 35-year history, and recognizing the need to continue supporting research and development for rare diseases.
About This Bill
Committee
Latest Action · November 16, 2018
Referred to the House Committee on Energy and Commerce.
Applauds the growth in research and development into new therapies for rare diseases and the resulting number of FDA-approved therapies for those living with rare diseases, and affirms the need to continue supporting such research and development.
Recognizes that significant research and development efforts and related investments are needed to develop therapies to treat and cure thousands of rare diseases for which no treatment options are currently available.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.